Ultragenyx Targets 2027 Profitability and $1 Billion Revenue
Ultragenyx Pharmaceutical said it expects to become profitable in 2027, with revenue approaching $1 billion that year, executives told investors at the UBS Global Biopharma Conference. Chief Executive Emil Kakkis described the expected profitability as meaningful and tied the outlook to lower spending, growing sales of the company's existing rare-disease therapies and the launch of two gene therapies.
The forecast follows a period of setbacks for the company, and it comes after deep cost reductions. Ultragenyx reported revenue of 673.0 million USD in fiscal 2025 alongside a net loss of 575.0 million USD for the same year.
The company's next scheduled earnings report is set for Feb 11, 2027, when investors are expected to see early progress against the 2027 goals.
Important questions to consider
Executives said the company expects to reach profitability in 2027 and is heading toward $1 billion in revenue that year. CEO Emil Kakkis characterized the expected profitability as meaningful, speaking at the UBS Global Biopharma Conference.
Ultragenyx recorded revenue of 673.0 million USD in fiscal 2025 and a net loss of 575.0 million USD for the year. The 2027 revenue goal would therefore represent a substantial step up from that base.
Management pointed to reduced spending after deep cuts, continued growth in sales of its existing rare-disease treatments, and the launches of two gene therapies. The company's next earnings report is scheduled for Feb 11, 2027.
Sources
- Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
Defense World
- Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha
- Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
MarketBeat